Zhimin Shao

Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer

Andrew Tutt, Judy E. Garber, Bella Kaufman et al. · New England Journal of Medicine · 2021 · 1.6K citations · Full text

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial

Sara A. Hurvitz, Fabrice André, Zefei Jiang et al. · The Lancet Oncology · 2015 · 300 citations

Breast Oncology, Oncology, Pharmacology +7

Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia

Zhimin Shao, Da Pang, Hongjian Yang et al. · JAMA Oncology · 2019 · 184 citations · Full text

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial

Nadia Harbeck, Chiun‐Sheng Huang, Sara A. Hurvitz et al. · The Lancet Oncology · 2016 · 150 citations

Breast Oncology, Previous Trastuzumab Treatment, Medicine +8

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib

Leiping Wang, Qunling Zhang, Jian Zhang et al. · BMC Cancer · 2011 · 145 citations · Full text